Cell line · CVCL_0219
COLO 320DM
Cancer cell line, Homo sapiens. Colon adenocarcinoma. 33 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Cite this record
ConductScience Library. COLO 320DM. Cell lines, record CVCL_0219. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0219
On this page
Cell line
As Cellosaurus gives it.
- Name
- COLO 320DM
- Accession
- CVCL_0219
- RRID
- RRID:CVCL_0219
- Synonyms
- COLO-320DM, COLO_320DM, COLO-320-DM, COLO #320DM, COLO320/DM, COLO320-DM, COLO320DM, Colo320DM, COLO320 DM, COLO 320 DM, COLO 320 (DM), Colorado 320 Double Minutes
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 55Y
- Category
- Cancer cell line
- Diseases
- Colon adenocarcinoma (NCIt C4349)
- Derived from
- Colon, sigmoid (in situ)
- Parent
- COLO 320 (CVCL_1989)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers33
4 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Basroparib inhibits YAP-driven cancers by stabilizing angiomotin. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Diverse oncogenes use common mechanisms to drive growth of major forms of human cancer. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Selective Depletion of Cancer Cells with Extrachromosomal DNA via Lentiviral Infection. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The E3 Ligase NEDD4L Prevents Colorectal Cancer Liver Metastasis via Degradation of PRMT5 to Inhibit the AKT/mTOR Signaling Pathway. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Reduced chemokine C-C motif ligand 1 expression may negatively regulate colorectal cancer progression at liver metastatic sites. | J Cell Mol Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors. | Mol Cancer Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BRD3 eradicates nuclear TYRO3-induced colorectal cancer metastasis. | Sci Adv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models. | Cancer Res Commun | 2022 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 33
See all 33 papersRelatives13
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Parent | COLO 320 | CVCL_1989 | Cell lines | |
| Derived from it | COLO 320DM#3 | CVCL_A6UJ | Cell lines | |
| Derived from it | COLO 320DM#3 SIRT1 KO cl.1 | CVCL_A6UK | Cell lines | |
| Derived from it | COLO 320DM#3 SIRT1 KO cl.2 | CVCL_A6UL | Cell lines | |
| Derived from it | COLO 320DM#3 SIRT1 KO cl.3 | CVCL_A6UM | Cell lines | |
| Derived from it | COLO 320DM#3 SIRT1 KO cl.4 | CVCL_A6UN | Cell lines | |
| Derived from it | COLO 320DM#3 SIRT1 KO cl.5 | CVCL_A6UP | Cell lines | |
| Derived from it | COLO 320DM#3 SIRT1 KO cl.6 | CVCL_A6UQ | Cell lines | |
| Derived from it | COLO 320DM-EGFP | CVCL_XD07 | Cell lines | |
| Derived from it | COLO 320DM-RFP | CVCL_XD08 | Cell lines |
1 to 10 of 13
See all 13 relativesCell banks8
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CCL-220 | ATCC | |
| BCRC | 60108 | BCRC | |
| CCTCC | GDC0042 | Cellosaurus | |
| CLS | 300153 | CLS | |
| ECACC | 87061205 | ECACC | |
| JCRB | JCRB0225 | JCRB | |
| KCB | KCB 200694YJ | Cellosaurus | |
| KCLB | 10220 | KCLB |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0219
GET https://conductscience.org/api/cell-lines/v1/CVCL_0219/papers?page=2